Firmonertinib misses primary endpoint in Phase 3 FURVENT trial in EGFR exon 20 NSCLC
ArriVent BioPharma, Inc. announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR). Clinical benefit was observed with secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. Although not yet mature, a trend toward an improvement in overall survival was also observed. The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified.
“These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options. While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study. We are deeply grateful to the patients, investigators and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib.” – Bing Yao, Ph.D., Chairman, Chief Executive Officer of ArriVent.
Key Results from the Phase 3 FURVENT Trial
The FURVENT key results are summarized below.
BICR:
Firmonertinib 240mg median PFS: 11.0 months.
Firmonertinib 160mg median PFS: 8.4 months.
Control median PFS: 9.5 months.
p-value (240mg vs. control): 0.0654.
HR (95% CI), 240mg vs Control: 0.75 (0.55, 1.02).
HR (95% CI), 160mg vs Control: 0.91 (0.67, 1.25).
Confirmed ORR 240mg: 60%.
Confirmed ORR 160mg: 35%.
Confirmed ORR control: 33%.
Investigator’s Assessment:
Firmonertinib 240mg median PFS: 11.1 months.
Firmonertinib 160mg median PFS: 8.3 months.
Control median PFS: 7.1 months.
HR (95% CI), 240mg vs Control: 0.61 (0.46, 0.81).
HR (95% CI), 160mg vs Control: 0.86 (0.65, 1.14).
Confirmed ORR 240mg: 61%.
Confirmed ORR 160mg: 41%.
Confirmed ORR control: 28%.
The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified. Treatment-emergent adverse events (TEAE) Grade ≥ 3 were 52% with firmonertinib 240mg, 53% with firmonertinib 160mg, and 55% with the control arm. Treatment-related adverse events (TRAE) Grade ≥ 3 were 26% with firmonertinib 240mg, 22% with firmonertinib 160mg, and 40% with the control arm.




